Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 21,500 shares, a decline of 91.6% from the May 15th total of 256,500 shares. Based on an average daily volume of 18,900 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.7% of the company's stock are short sold.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new position in Bolt Biotherapeutics during the fourth quarter valued at $25,000. Squarepoint Ops LLC acquired a new position in Bolt Biotherapeutics during the fourth quarter valued at $26,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics during the fourth quarter valued at $27,000. Finally, Citadel Advisors LLC acquired a new position in Bolt Biotherapeutics during the fourth quarter valued at $42,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on BOLT. Stifel Nicolaus cut their price target on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a "hold" rating on the stock in a report on Tuesday, May 13th. Lake Street Capital began coverage on shares of Bolt Biotherapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $80.00 price target on the stock. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Bolt Biotherapeutics in a report on Tuesday, March 25th.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT traded down $0.13 on Friday, hitting $6.10. 11,148 shares of the company were exchanged, compared to its average volume of 10,664. Bolt Biotherapeutics has a 1-year low of $5.20 and a 1-year high of $15.60. The stock's 50 day moving average price is $6.73 and its 200 day moving average price is $8.78. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $11.69 million, a P/E ratio of -3.57 and a beta of 0.91.

Bolt Biotherapeutics (NASDAQ:BOLT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($5.80) EPS for the quarter, topping the consensus estimate of ($6.80) by $1.00. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $1.22 million during the quarter, compared to the consensus estimate of $0.77 million. Sell-side analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.